TITLE

In vitro effects of polyvalent immunoglobulin for intravenous use

AUTHOR(S)
van Schaik, I N; Vermeulen, M; Brand, A
PUB. DATE
November 1994
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Nov1994 Supp, Vol. 57, p15
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
No abstract available.
ACCESSION #
66105651

 

Related Articles

  • Intravenous immunoglobulin as clinical immune-modulating therapy. Gilardin, Laurent; Bayry, Jagadeesh; Kaveri, Srini V. // CMAJ: Canadian Medical Association Journal;3/3/2015, Vol. 187 Issue 4, p257 

    The article discusses the impact of intravenous immunoglobulin on the immune system. Topics include the evidence supporting immunoglobulin's use as an immune-modulating agent, diseases in which intravenous immunoglobulin is effective, such as neurologic disorders, autoimmune mucocutaneous...

  • Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines. Frenzel, K.; Ganepola, S.; Michel, D.; Thiel, E.; Krüger, D.; Uharek, L.; Hofmann, J. // Medical Microbiology & Immunology;Aug2012, Vol. 201 Issue 3, p277 

    Primary infection and reactivation of human cytomegalovirus (CMV) remain a major problem in immunocompromised patients, frequently resulting in a life threatening CMV disease. Intravenous polyvalent (hyper)-immunoglobulins (IVIG) can be administered for therapy and prophylaxis of CMV infections....

  • Aseptic Meningitis and Intravenous Immunoglobulin Therapy . Scribner, Curtis L.; Kapit, Richard M.; Phillips, Evelyne T.; Rickles, Nathaniel M. // Annals of Internal Medicine;8/15/94, Vol. 121 Issue 4, p305 

    Editorial. Deals with the association of aseptic meningitis syndrome with the use of intravenous immunoglobulin. Side effects reported with infusions of intravenous immunoglobulin; Information on U.S. Food and Drug Administration MEDWatch system; Indication for administration of intravenous...

  • Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone. Trappe, R.; Riess, H.; Anagnostopoulos, I.; Neuhaus, R.; Gärtner, B.; Pohl, H.; Müller, H.; Jonas, S.; Papp-Vary, M.; Oertel, S. // Annals of Hematology;Feb2009, Vol. 88 Issue 2, p167 

    A letter to the editor is presented discussing the efficiency of antiviral therapy with polyvalent intravenous immunoglobulins (IVIG) in Epstein-Barr virus (EBV) linked to posttransplant lymphoproliferative disorder (PTLD) refractory to rituximab and chemotherapy.

  • A revival for immunoglobulin therapy in septic shock? Textoris, Julien; Calandra, Thierry; Pène, Frédéric // Intensive Care Medicine;Dec2014, Vol. 40 Issue 12, p1957 

    The article explores the utilization of immunoglobulins in the treatment of septic shock. The therapeutic potential of polyvalent intravenous immunoglobulin (IVIG) preparations in septic patients is highlighted. The authors review a study which failed to identify any significant baseline...

  • Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Högy, Barbara; Keinecke, Heinz-Otto; Borte, Michael // European Journal of Health Economics;Mar2005, Vol. 6 Issue 1, p24 

    Primary antibody deficiencies are the most common forms of primary immunodeficiencies. Substitution therapy with polyvalent immunoglobulins has been established as the standard therapy for antibody deficiencies for several decades. Until now mainly intravenous immunoglobulins (IVIG) have been...

  • IVIG trials in MS. Is albumin a placebo? Hommes, Otto; Haas, Judith; Soelberg-Sorenson, Per; Friedrichs, Mieke // Journal of Neurology;Feb2009, Vol. 256 Issue 2, p268 

    A letter to the editor is presented on the effects of intravenous immunoglobulin treatments for multiple sclerosis patients.

  • Intravenous Immunoglobulins as Therapeutic Agents. Stiehm, E. Richard; Ashida, Ellyn; Kim, Kwang Sik; Winston, Drew J.; Haas, Albert; Gale, Robert P. // Annals of Internal Medicine;Sep87, Vol. 107 Issue 3, p367 

    Investigates the therapeutic efficacy of intravenous immunoglobulins for treating secondary antibody immunodeficiency. Disadvantages of intraveneous immunoglobulins; Side effects of the treatment; Importance of intraveneous immunoglobulins for preventing certain types of viral infection.

  • Bedeutung intravenöser Immunglobuline zur Behandlung immunvermittelter Polyneuropathien. Stangel, M.; Hartung, H.-P.; Gold, R.; Kieseier, B.C. // Der Nervenarzt;Jun2009, Vol. 80 Issue 6, p678 

    Long-term treatment of immune-mediated polyneuropathies remains difficult. For acute polyneuritis, or Guillain-Barré syndrome, the established standard therapy utilizes high doses of polyvalent intravenous immunoglobulins (IVIG). A recently published randomized placebo-controlled study of...

  • Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia. Marković-Sovtić, Gordana; Janković, Borisav; Rakonjac, Zorica; Martić, Jelena; Pejić, Katarina // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Nov2013, Vol. 70 Issue 11, p1029 

    Background/ Aim. Intravenous immunoglobulin is a blood product made of human polyclonal immunoglobulin G. The mode of action of intravenous immunoglobulin is very complex. It is indicated in treatment of neonatal immune thrombocytopenia and haemolytic disease of the newborn. The aim of the study...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics